Centessa still finding itself as it cuts another program

11 August 2022

A pharma company created last year with the merger of 10 privately-held biotech companies has cut a second drug program of the summer.

Centessa Pharmaceuticals (Nasdaq: CNTA) closed Wednesday’s trading 5% lower after announcing - alongside its second-quarter financial results - that it is to discontinue development of its Phase I asset ZF874.

This follows a recent report of an adverse event involving elevated liver enzymes (AST/ALT) in a PiMZ genotype patient given 5 mg/kg of ZF874 twice daily in the Phase I study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK